Skip to content

Beacon Biosignals

1 viewer · 30d

Total raised

$103.3M

1 filing since 2025 · latest Equity filed

Cumulative raised
LAST ROUND
Equity · $103.3M
ROUNDS
1
INVESTORS
43
FOUNDED
N/A
HQ
Boston, MA
SECTOR
Healthcare
EMPLOYEES
N/A
30D VIEWERS
1

AI overview

Updated

Beacon Biosignals is a neurotechnology company that applies machine learning to EEG (electroencephalography) data to measure brain activity for drug development and clinical care. Its platform collects, integrates, and analyzes neurophysiology data across Phase 1-4 clinical trials, and its FDA 510(k)-cleared wearable headband brings sleep-stage EEG recording out of the sleep lab and into patients' homes. The company reports more than 2 million hours of EEG analyzed, over 500,000 home sleep tests completed, and support for 40+ clinical trials. It was founded in 2019 by Jacob Donoghue and Jarrett Revels and is headquartered in Boston, Massachusetts.

What sets it apart

Pairs an FDA-cleared at-home EEG wearable with AI analytics trained on what the company describes as the world's largest clinically validated neurophysiology dataset, letting sponsors capture multi-night, real-world brain data instead of single-night lab polysomnography.

Funding history

1 round
EquityOct 7, 2025
Form D
+$103.3M$103.3M total

Latest SEC filings

via EDGAR · CIK 0001765647
Form D · Oct 7, 2025View on EDGAR

Products

1 tracked

Beacon Biosignals EEG platform

Clinical trial neurodiagnostics platform

A precision-medicine platform for collecting, integrating, and analyzing EEG data across the drug development lifecycle, from trial design through biomarker discovery and patient stratification.

  • AI/ML analysis of EEG recordings for biomarker discovery
  • Support across Phase 1-4 clinical trials
  • Patient stratification and endpoint measurement for CNS programs
  • At-home, multi-night data collection in patients' natural environments

Links

WebsiteLinkedInSEC EDGAR filings